MacroGenics Stock Crashes 38% on 'Positive' Trial Data

The Short Answer

MacroGenics stock crashed 38.02% on Friday, October 23, 2026 — on the same day the company announced what it called "positive" Phase 1 trial data. MacroGenics (NASDAQ: MGNX) closed at $2.25, down $1.38 from $3.63, after it presented interim results for MGC026, its B7-H3-directed cancer drug, at the ESMO 2026 Congress in Madrid. The headline numbers — a 27% response rate in hard-to-treat head and neck cancer — were real. So were the reasons traders sold anyway: only four responses were confirmed, half of treated patients had severe treatment-related side effects, and the next major milestones are not expected until 2027.

What Happened

MacroGenics, a clinical-stage biotech based in Rockville, Maryland, released the data on Friday morning, October 23, in a Globe Newswire announcement and an ESMO presentation. MGC026 is an antibody-drug conjugate — an antibody designed to find B7-H3, a protein found on many solid tumors, and deliver a potent TOP1 inhibitor payload directly to the cancer cells.

The trial covered patients with advanced solid tumors who had already been heavily treated. As of the September 1, 2026 data cutoff, 85 patients had been treated across the dose-escalation and dose-expansion parts of the study.

The market reaction was immediate and one-directional. The stock opened essentially flat at $3.55 and was sold steadily through the session, trading between $2.13 and $3.56 before closing at $2.25. About 4.00 million shares changed hands — roughly 6.85 times the stock's average volume of about 584,000 shares — cutting the company's market value to roughly $229 million.

The Trial Numbers, Up Close

Response rate in head and neck cancer: In recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), 6 of 22 response-evaluable patients had partial responses — a 27% best overall response rate. Four of those responses were confirmed and two were unconfirmed, and the company reported a 64% disease control rate in that group.

Durability signal: Among 17 dose-escalation patients treated at doses of 6 mg/kg or higher across solid tumor types, the confirmed response rate was 29%, with a median response duration of 10.2 months — the detail supporters of the drug point to most.

Safety: Grade 3 or worse treatment-related adverse events occurred in 51% of the 85 treated patients. The most common severe effects were neutropenia (27%) and anemia (25%). Treatment-related events led 5% of patients to discontinue, there were no Grade 5 treatment-related events, and the company reported no cases of interstitial lung disease, pneumonitis or ocular toxicity — and no treatment-related discontinuations among the SCCHN patients specifically.

"The emerging profile of MGC026 reinforces our conviction that this molecule has the potential to play an important and differentiated role in the treatment of advanced solid tumors," said President and CEO Eric Risser in the release.

Why It's Blowing Up: "Positive" Data, Negative Verdict

This is a classic biotech pattern: the press release says one thing and the share price says another, and both can be honest. MacroGenics framed the readout as positive because responses were durable, a dose was selected, and the drug can move into a front-line combination study. Traders focused on the harder arithmetic — four confirmed responses out of 22 patients is a small base, a 51% rate of severe treatment-related side effects is a heavy burden to carry into combination therapy, and Friday's volume, nearly seven times normal, showed institutions were not waiting around to debate it.

Timing added to the pressure. The planned front-line SCCHN cohort, testing MGC026 together with pembrolizumab, is a registrational path that points to early 2027, with updated data expected around mid-2027. For a small-cap biotech stock, a catalyst that far away gives sellers a reason to leave now and revisit later. None of that makes the science a failure — Phase 1 trials are designed to find a dose and an early signal, and MGC026 produced both — but it does explain why a "positive" headline produced a 38% loss.

What's Next

The next chapter is the front-line combination study in metastatic SCCHN, pairing MGC026 with pembrolizumab, which the company says it plans to initiate. Updated MGC026 data is expected around mid-2027. Until then, MGNX is likely to trade on financing, partnership and pipeline headlines rather than on this dataset alone. This post reports what happened and why markets reacted; it is not a recommendation to buy, sell or hold any security.

Sources

FAQ

Why did MacroGenics stock fall 38% on positive trial news?

MGNX closed down 38.02% at $2.25 on October 23, 2026 because traders focused on the details behind the "positive" headline: only 4 of 22 head and neck cancer responses were confirmed, 51% of patients had Grade 3 or worse treatment-related side effects, and the next major milestones sit in 2027.

What is MGC026?

MGC026 is MacroGenics' B7-H3-directed antibody-drug conjugate for advanced solid tumors. It uses a selective antibody and a proprietary linker to deliver a TOP1 inhibitor payload to cancer cells.

What were the MGC026 Phase 1 results?

In heavily pretreated head and neck cancer, MGC026 posted a 27% best overall response rate (6 of 22 patients; 4 confirmed) and 64% disease control. At doses of 6 mg/kg or higher, the confirmed response rate was 29% with a median duration of 10.2 months.

What happens next for MacroGenics?

The company plans a front-line SCCHN study combining MGC026 with pembrolizumab, with the registrational path pointing to early 2027 and updated data expected around mid-2027.

MacroGenics Stock Crashes 38% on 'Positive' Trial Data — Why MGNX Sold Off Anyway